Summary
Introduction
Spectrum Pharmaceuticals (Spectrum) is a biopharmaceutical company with a diversified portfolio of generic products and a pipeline of proprietary and collaborative products. Its therapeutic focus is on various cancer indications, infections and other diseases. The company product revenues are primarily from generic product sales.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Spectrum develops in-licensed drugs for the treatment and supportive care of cancer patients. The company also has a pipeline of pre-clinical neurological drug candidates for disorders such as attention-deficit hyperactivity disorder, schizophrenia, mild cognitive impairment and pain. The company's total revenues increased at a CAGR of 24% during 2002-2006 from $2 million to $6 million. The company derived revenues from product sales from 2004. Product sales from $0.2 million in 2004 to $0.1 million in 2006, primarily due to competitive market for generic products. Spectrum's total revenues between 2006 and 2010 are forecasted to grow at a CAGR of 16% from $6 million to $10 million. This represents an absolute growth of +$4 million solely contributed by the company's product ISO-Vorin [Levofolinic acid (LFA)] for cancer indications. Spectrum is expected to launch ISO-Vorin in 2008.
Reasons to Purchase
Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization .
|
